| |
No=25 |
20% |
| Age |
|
|
| median |
46 |
|
| Range |
22-64 |
|
| Pre chemotherapy |
|
|
| Tumor size |
Between 2.5-6 cm diameters with average size 3.5 ± 0.6cm |
|
| |
25/25 |
-100% |
| Axillary nodes +ve |
25-Dec |
-48% |
| Multifocal |
25-Apr |
-16% |
| Multicentric disease |
|
|
| ER |
|
|
| *ve |
18/25 |
72% |
| -ve |
7/25 |
28% |
| PR |
|
|
| +ve |
16/25 |
64% |
| -ve |
25-Sep |
36% |
| HER 2 |
|
|
| +ve |
25-May |
20% |
| -ve |
20/25 |
80% |
| ki67 |
|
|
| <14 |
25-Jan |
4% |
| >14 |
24/25 |
96% |
| Histopathology |
|
|
| IDC |
21/25 |
84% |
| ILC |
25-Apr |
16% |
| NAC |
|
|
| 3 cycles FEC 3cycles docetaxale. |
25/25 |
100% |
| Herceptine |
25-Apr |
16% |
| Operative data : |
|
|
| Conservation surgery |
20/25 |
80% |
| Mastectomy |
25-May |
20% |
|
